B Lymphocytes Are the Target of Mesenchymal Stem Cells Immunoregulatory Effect in a Murine Graft-versus-Host Disease Model

Di Lu1,2,3, Tian Ma1, XiangBin Zhou2,4, YanMing Jiang5, Yan Han1, and Hong Li2,3

Abstract
There is growing clinical interest in the utilization of mesenchymal stem cells (MSCs) in the management of acute graft-versus-host disease (aGvHD), yet the effect of major histocompatibility complexes (MHCs) on B lymphocytes in this process has been less well documented. Working in an MHC fully mismatched murine aGvHD model, we found that MSC co-transfer significantly prolonged the survival time of the recipients. More interestingly, analysis on immunophenotypic profiles of posttransplant splenocytes showed that surface expression of CD69 (an early activation marker) and CD86 (a costimulatory molecule) was suppressed predominantly on donor derived B lymphocytes by MSC infusion. Additionally, mRNA level of interleukin-4, a potent B lymphocyte stimulator, was strikingly reduced from MSC-treated mice, while interleukin-10, the regulatory B lymphocytes inductor, was increased; these may underlie the lesser activation of B lymphocytes. In consistence, depletion of B lymphocytes in the transfusion inoculum further prolonged the survival time of aGvHD mice regardless of MSC administration. Therefore, B lymphocytes played an important role in the development of aGvHD, and they are targets in MSC-regulated immune response cascade in vivo. This study may provide a mechanistic clue for the treatment of human clinical aGvHD.

Keywords
Mesenchymal stem cells, acute graft-versus-host disease, B lymphocyte, CD69

Introduction
Acute graft-versus-host disease (aGvHD) continues to be a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), which significantly limits the successful outcome of HSCT in the treatment for a number of hematologic malignancies. aGvHD usually manifests within 100 days following HSCT. Clinically significant aGvHD (grade II or higher) developed in 20–65% of patients. Mortality due to this complication accounts for approximately 50%1,2.

T lymphocytes are the main actor in aGvHD development. aGvHD is mediated by the cytotoxic T lymphocytes attacking3–5. The pathogenesis of aGvHD can be divided into three sequential steps6,7. The myelosuppressive conditioning regimen causes tissue damage that leads to a pro-inflammatory environment and antigen-presenting cell activation. Donor T cells activation and proliferation are induced by the pro-inflammatory milieu. The activated allogeneic T cells induce apoptosis of target cells and secrete pro-inflammatory cytokines, enhancing aGvHD.
Mesenchymal stem cells (MSCs) are a progenitor cell population with multilineage potency. MSCs were initially discovered in bone marrow and were subsequently found in almost every type of tissue, such as adipose tissue, dental pulp, amnion, and umbilical cord8–9. A large number of studies have demonstrated that MSCs are low allogenic stimulators and may even suppress an ongoing immune process, in which T lymphocytes10–13 and dendritic cells14,15 are involved. In light of their immunoregulatory properties and ease of in vitro expansion, MSCs have been utilized clinically to treat patients with aGvHD, especially in the treatment of steroid-refractory aGvHD16. Clinical data suggest the complete response to MSC treatment of patients to be about two-thirds17–19. The incidence of cytomegalovirus, Epstein–Barr virus infections, and tumor relapse was not different between the non-MSCs group and the MSCs group during aGvHD treatment and follow-up20.

B lymphocytes have been considered as effector cells in chronic GVHD21,22. MSCs have been reported to regulate B lymphocyte activation in vitro and in vivo23,24. Previous studies about the immunoregulatory effects of MSCs on B lymphocytes mainly related to the B lymphocyte maturation and immunoglobulin section functions25. Rosado et al. reported that inhibition of B-cell proliferation and antibody production by MSCs was mediated by T cells26.

B lymphocytes can also be competent antigen-presenting cells for delivery of protein antigens to CD4+ T cells in vivo27. Up to now, the basic question of how MSCs act on B lymphocytes in aGvHD remains rarely documented. Our previous study revealed that the functional and phenotypic alteration of T lymphocytes was affected by MSCs in the aGvHD model28. In the present study, we examined the immunoregulatory effect of MSCs on B lymphocytes. The results revealed that donor B lymphocytes played an important role in the development of aGvHD. MSCs potentely inhibited the expression of CD69 and CD86 on B lymphocytes, and B lymphocyte deletion further prolonged the mean survival time (MST) of aGvHD mice.

Materials and Methods

Cell Culture

Primary MSCs were isolated from C57BL/6 (B6) murine compact bone fragments, and culture-expanded as described in our previous report29. Cells were grown in minimal essential medium (GIBCO, Grand Island, NY, USA) with 4 mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, and 10% fetal bovine serum in a humidified atmosphere of 5% CO₂ at 37°C.

Murine aGvHD Model

aGvHD was induced as previously described with some modifications30. Briefly, inoculum of 7 × 10⁶ unfractonated B6 (H2b) nucleated spleen cells, with or without MSCs (1 × 10⁴), was intravenously injected into sublethally irradiated (⁶⁰Co, 5 Gy) female recipient BALB/c (H2d) aged 6–8 weeks, which were designated as aGvHD+MSCs or aGvHD group respectively. Syngeneic controls received BALB/c splenocytes (7 × 10⁷). In some experiments, splenocytes (3.85 × 10⁵) immuno-magnetically depleted of B220+ cells (B lymphocytes at all stages) were used with or without co-transfer of MSCs (B220+/aGvHD+MSCs or B220+/aGvHD group).

Alloreactive Cytotoxic Assay

Aliquots (2 × 10⁶) of nucleated splenocytes of aGvHD and aGvHD+MSCs harvested on day 5 were cultured in triplicate in 96-well plates with ³H-TdR-labeled P815 cells (H2a) for 5 h, at an effector/target ratio of 40:1. The percent specific cytolyis was determined as follows: specific lysis (%) = (cpm maximum – cpm experimental)/ cpm maximum.

Flow Cytometry Analysis

At different posttransplant time points, nucleated splenocytes from two or three mice were pooled and surface stained with fluorescein isothiocyanate or phycoerythrin-conjugated monoclonal antibodies. Antibodies against mouse CD3 (145-2C11), H2b (28-8-6) were purchased from BD-Pharmingen (BD Biosciences, San Jose, CA, USA). Antibodies against mouse CD11b (M1/70), mlgM (RMM-1), CD69 (H1.2F3), CD86 (GL-1), CD25 (3C7) and CD4 (GK1.5) were from BioLegend (San Diego, CA, USA). Cells were examined on a FACSCalibur with CellQuest software (BD Biosciences). Data were analyzed using FlowJo 7 software (Joseph Trotter, La Jolla, CA, USA). Acquired events were gated for the designated population.

Real-time Polymerase Chain Reaction

At different posttransplant time points, B220 positive splenocytes from aGvHD were collected by magnetic bead sorting (R&D Systems, Minneapolis, MN, USA) and total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed as described by the manufacture's instructions (TOYOBO, Osaka, Japan). The primers are: interleukin (IL)-4: upper, 5'-CCATATCCAGGTGC GACA-3', lower, 5'-CTGTGGTGTTCTTCGTGCT-3'; IL-10: upper, 5'-GGCCCAAGAATCAAGGA CGA-3', lower, 5'-ACAGGGGAAATCGATGACAG-3'; HPRT: upper, 5'-AGCCTAAGATGAGGCGCAAGT-3', lower, 5'-GCCCACAGGACTAGAACACC-3'. The levels of gene expression were calculated by relative quantification using HPRT as the endogenous reference genes. The gene expression level at the time point of 12 h post transplantation was designated as 1.
Statistical Analysis

Statistical analysis was performed using Prism 6 (GraphPad Software, San Diego, CA, USA). The Kaplan–Meier product-limit method was used to calculate survival curve. Differences between groups in survival studies were determined using log-rank statistics. Statistical analysis was performed with the log-rank test or the Student t test. p value less than 0.05 was considered statistically significant.

Results

MSCs Infusion Prolonged the MST of aGvHD Mice

In agreement with the clinical trials, alleviation of aGvHD severity by co-transfer of expanded MSCs was also evident in this study, in that the MST of MSC co-infusion in mice was significantly prolonged (7.89 ± 0.73 days for aGvHD+MSCs group vs. 5.31 ± 0.45 days for aGvHD group, n = 15, p < 0.05). Correspondingly, by day 5, the anti-H2d (P815 cells) cytotoxicity of posttransfusion splenocytes was significantly reduced (Fig. 1A), which suggests that MSC treatment suppressed anti-host (H2b) reactivity of donor derived T lymphocytes (H2b).

MSC Infusion Significantly Down-regulated the Expression of CD69, an Early Activation Marker, on B Lymphocytes

CD69 is known as a very early activation marker; it is upregulated on T cells during the first kinetics phase of brief contacts between T cells and antigen presenting cells. We, then, attempted to define cellular events involved in MSC functionality by characterizing the phenotypes of splenocytes harvested 12 h, 24 h, 48 h, day 3, and day 5 post-transplantation, focusing on surface activation marker expression. Flow cytometry analysis showed that CD69 expression exhibited an inverse “V” curve, peaking at 24 h, and MSC co-transfer down-regulated CD69 expression obviously at 12 h and 24 h. The percentage dropped from...
41.0 ± 4.2% to 33 ± 5.0%, and from 63.5 ± 3.8% to 48.5 ± 4.7% for aGvHD and aGvHD+MSCs groups respectively (Fig. 1B, C).

Nevertheless, percent CD69 reduction in CD3⁺ cells was not obvious (1.2–5.0% of all spleen mononucleated cells), in apparent contrast to that in the CD3⁻ population.
(Figs 1C, 2A). Then, its expression on mature B lymphocytes (membrane IgM, mIgM⁺), monocytes (CD11b⁺), and natural killer (NK) cells (NK1.1⁺) between the two groups was compared separately. Interestingly, decrease of percent CD69 in mature B lymphocytes was predominantly evident, as the proportion was 72.0% (63.4–85.3%) of total CD69⁺ cells at 12 h (Fig. 2B) and 58.8% (49.6–72.3%) at 24 h. A decline of percent CD69 was also observed in CD11b⁺ cells, but it contributed less to the total decrease (Fig. 2C). The proportion of NK cells was extremely low in the aGvHD recipient mice. Therefore, they had few contributions to the CD69 expression (Fig. 3).

The Co-stimulatory Molecule CD86 Decreased by MSC Infusion

B lymphocytes are a kind of antigen-presenting cell, but the contribution is controversial as they can either prime naïve T cells or induce T cell anergy, depending partially on surface co-stimulatory molecule expression. In this study, we found that over 75% of IgM⁺ cells were positive for CD86 molecule at 12 h and 24 h (Fig. 4A, C). Similar to CD69 expression, MSC co-transfer also down-regulated CD86 expression on B lymphocytes at all observing time points after transplantation (6 h, 12 h, 24 h, day 3, day 5), implying that MSCs exert immunoregulatory effects by down-regulating alloantigen presenting function of B to T lymphocytes.

It was also noteworthy that most IgM⁺ cells co-expressed H2b at 12 h and afterwards post transplantation (Fig. 4D), indicating the donor origin of the activated B lymphocytes. Therefore, our results linked B lymphocytes to MSC-regulated immune response cascade in vivo.

B Lymphocyte Deletion Further Prolongs the MST of Mice of aGvHD and aGvHD+MSCs Groups

To confirm the functional role of B lymphocytes in this experimental model, we depleted B220⁺ cells (B lymphocytes at all stages) from the transfusion inoculum. The results showed that the MST was prolonged significantly when compared with the aGvHD group with B220⁻/aGvHD group (5.31 ± 0.45 days vs. 10.00 ± 2.10 days, p = 0.0167), the aGvHD+MSCs with B220⁻/aGvHD+MSCs (7.89 ± 0.73 days vs. 12.53 ± 2.71 days, p = 0.00256) (Fig. 5A), indicating that B lymphocyte activation was a critical step in the development of aGvHD. Nevertheless, there were no differences between the B220⁻/aGvHD and B220⁻/aGvHD+MSCs group of mice, which indicates that B lymphocytes are the target of MSC regulation in vivo.

We further analyzed the cytokine profiles of splenic B220⁺ cells of aGvHD and aGvHD+MSCs by qRT-PCR. As indicated in Fig. 5B, the mRNA level of IL-4, a well-characterized potent stimulator for B lymphocytes, was remarkably down-regulated at every time point, implying that suppression of B lymphocyte activation by MSCs might be at least partially attributed to decreased IL-4 autocrine. Also, MSCs up-regulated IL-10 expression, but these changes occurred at late stages, when B lymphocyte activation declined. This change might be related to the formation of B regulatory cells.

In the B220⁻/aGvHD and B220⁻/aGvHD+MSCs groups of mice the membrane IgM positive cells were almost deleted by the B220 antibody at the 24 h time point after infusion, whatever host (H2b⁻) or donor (H2b⁺) derived (Fig. 5C), therefore, the CD69 and CD86 expression was mainly concentrated in the IgM negative cells. CD69 expression on the CD3 positive T lymphocytes was significantly lower than those of the aGvHD and aGvHD+MSCs mice (Fig. 5C), which may explain the prolonged MST by B220 deletion. In this aGvHD model, the syno-splenic cell infusion mice acted as the control group, the mice were alive long-term (Fig. 5A), and very few T and B lymphocyte were activated (Fig. 5D).

Discussion

MSCs play a key role in the regulation of the immune responses against allo- and auto-antigens, and have been employed in clinical trials to treat steroid-resistant aGvHD. Our study revealed that B lymphocytes are targets of MSCs’ immunoregulatory effect and play an important role in the development of aGvHD.

aGvHD is a life-threatening complication of allogeneic HSCT. Previous efforts emphasized the crucial role of T cells in the development of aGvHD. CD69 is a
membrane-bound, type II C-lectin receptor. It is known that CD69 is a classical early marker of T lymphocyte activation during the first kinetics phase of brief contacts between T cells and antigen presenting cells, as it rapidly appears on the surface of the plasma membrane after stimulation. Cross-linking of CD69 by monoclonal antibody induced a prolonged elevation of intracellular [Ca\(^{2+}\)], which was induced by the influx of extracellular Ca\(^{2+}\). This signal resulted in ERK1/2 kinases activation.

Fig. 4. Mesenchymal stem cell (MSC) infusion decreased the CD86 expression on B lymphocytes, which were predominantly donor derived. A. CD86 expression on B lymphocytes indicated by the ratio of CD86 and IgM double positive cells to IgM positive cells at different time point post infusion detected by flow cytometry (FCM) technique; \( n = 12 \), \(* p < 0.05\), **\( p < 0.01\). B. The proportion of donor derived B lymphocytes, which was displayed by the ratio of co-expressed H2b\(^{+}\) mIgM\(^{+}\) to mIgM\(^{+}\) B lymphocytes detected by FCM technique; \( n = 12 \). C, D. The representative flow cytometric density diagram of CD86 co-expression (C) and co-expressed H2b\(^{+}\) (D) on IgM\(^{+}\) B lymphocytes; \( n = 12 \). aGvHD: acute graft-versus-host disease.
induction of synthesis of IL-2 and interferon-γ, and cell proliferation. We examined the CD69 expression status at 6 h, 12 h, 24 h, day 3, and day 5 post transplantation. Our study demonstrated that MSC co-infusion surely downregulated CD69 expression on the mononucleated splenic cells of aGvHD recipient mice. However, CD69 up-regulation was not so obvious on the CD3⁺ T lymphocytes (Fig. 1C). CD69 is also promptly up-regulated on cells of most hematopoietic lineages, including B lymphocytes, macrophages, NK cells, etc.³⁶,³⁸,³⁹. Thus, the expression kinetics of CD69 on antigen presenting cell types is one of costimulatory molecules.¹⁰ Then we also examined CD69 expression status on the other cell subtypes. Our results indicated that the proportions of CD11b positive cells...
(monocytes, macrophages) and NK1.1 positive NK cells were very low. CD69 was significantly down-regulated on the B lymphocytes (Fig. 2B), therefore, this present study focused on what role of B lymphocytes play in the aGvHD and their relationship with infused MSCs.

Previous investigations revealed that MSCs can regulate B lymphocyte function. But the regulatory direction is mainly dependent on the treatment microenvironment. It was reported that treatment with human MSCs resulted in an increase of proliferation, differentiation of B lymphocytes into plasma cells, and production of antibodies in vitro. But it is also reported that mouse MSCs significantly enhanced T cell dependent and independent antibodies production in vivo mice41. Human palatine tonsil-derived MSCs ameliorate B-cell-mediated immune responses and increase IL-10 production42. Conditioned medium from cultivation of MSCs alone has no effect on B-cell expansion. MSCs need to be activated to exert their suppressive properties. Human MSCs and B lymphocytes were cocultured with different B-cell tropic stimuli. B-cell proliferation, maturation and production of IgM, IgG, and IgA was significantly impaired33,44. Transwell experiments indicated soluble factors were the major mechanism of B-cell suppression. The Corcione group reported that human MSCs also significantly down-regulated B-cell chemotaxis property to CXCL12, the CXCR4 ligand, CXCL13, and the CXCR5 ligand45.

An important function of B lymphocytes is antigen presenting. Corcione et al. reported that hMSCs did not affect the expression of B-cell costimulatory molecule, MHC-II, CD40, CD86, and CD80, and cytokine production, which indicated that the antigen presenting properties of B lymphocytes are not affected45. However, the immunoregulatory function exerting is dependent on the inflammatory circumstance exposure. Our present data demonstrated that MSCs potently inhibited the costimulatory molecule CD86 expression on B lymphocytes. These processes were more obvious at the early stage of aGvHD. To further investigate the B cells’ function in the development of aGvHD, B lymphocytes were deleted by B220 antibody. Data in Fig. 5 show that B lymphocyte deletion prolonged the MST of aGvHD mice. The MST was 5.31 ± 0.45 days for aGvHD group, 10.00 ± 2.10 days for B220+/aGvHD group, 12.53 ± 2.71 days for B220⁻/aGvHD+MSCs group. There was no difference between the B220⁻/aGvHD and B220⁻/aGvHD+MSCs group of mice. The underlying reason may be due to the critical role of B lymphocyte in aGvHD development, and B lymphocytes are a target of MSC regulation in vivo.

Conclusion
To the best of our knowledge, this study is the first to represent the evidence that MSCs target B lymphocyte function to inhibit the development of aGvHD. The cell activation and antigen presenting function of B lymphocytes was restrained by MSC infusion. This present study might shed light on therapeutic targets for the treatment of human clinical aGvHD.

Acknowledgment
The authors thank ZiKuan Guo for the kind help in manuscript writing.

Ethical Approval
This study was carried out in strict accordance with the recommendations in the national guidelines for the use of animals in scientific research “Regulations for the Administration of Affairs Concerning Experimental Animals.” Additional approval was granted by the Animal Care and Use Committee of Chinese PLA General Hospital, with the approval number PGH-16021103.

Statement of Human and Animal Rights
All experimental procedures were approved by the animal care committee of the Chinese PLA General Hospital.

Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this work was supported by National Natural Science Foundation of China (No. 81571619), the National Key Research and Development Program of China (Nos. 2016YFE0204400).

ORCID iD
Hong Li https://orcid.org/0000-0001-9984-3849

References
1. Shaw BE. Graft versus host disease clinical trials: is it time for patients centered outcomes to be the primary objective? Curr Hematol Malig Rep. 2019;14(1):22–30.
2. Jaglowski SM, Devine SM. Graft-versus-host disease: why have we not made more progress? Curr Opin Hematol. 2014;21(2):141–147.
3. Zhang L, Chu J, Yu J, Wei W. Cellular and molecular mechanisms in graft-versus-host disease. J Leukoc Biol. 2016;99(2):279–287.
4. Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute graft versus host disease: a comprehensive review. Anticancer Res. 2017;37(4):1547–1555.
5. Ferrara JLM, Chaudhry MS. GVHD: biology matters. Blood Adv. 2018;2(22):3411–3417.
6. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561.
7. Hulsdunker J, Zeiser R. Insights into the pathogenesis of GVHD: what mice can teach us about man. Tissue Antigens. 2015;85(1):2–9.
8. Berebichez-Fridman R, Montero-Olvera PR. Sources and clinical applications of mesenchymal stem cells: state-of-the-art review. Sultan Qaboos Univ Med J. 2018;18(3):e264–e277.
9. Nancarrow-Lei R, Mafi P, Mafi R, Khan W. A systemic review of adult mesenchymal stem cell sources and their multilineage differentiation potential relevant to musculoskeletal tissue repair and regeneration. Curr Stem Cell Res Ther. 2017;12(8):601–610.
10. Glenn JD, Smith MD, Calabresi PA, Whartenby KA. Mesenchymal stem cells differentially modulate effector CD8+ T-cell subsets and exacerbate experimental autoimmune encephalomyelitis. Stem Cells. 2014;32(10):2744–2755.
11. Crain SK, Robinson SR, Thane KE, Davis AM, Meola DM, Barton BA, Yang VK, Hoffman AM. Extracellular vesicles from wharton’s jelly mesenchymal stem cells suppress CD4 expressing T cells through transforming growth factor beta and adenosine signaling in a canine model. Stem Cells Dev. 2019;28(3):212–226.
12. Hong JW, Lim JH, Chung CJ, Kang TJ, Kim TY, Kim YS, Roh TS, Lew DH. Immune tolerance of human dental pulp-derived mesenchymal stem cells mediated by CD4(+)/CD25(+)FoxP3(+) regulatory T-Cells and induced by TGF-beta1 and IL-10. Yonsei Med J. 2017;58(5):1031–1039.
13. Milosavljevic N, Gazdie M, Simovic Markovic B, Arsenijevic A, Nurkovic J, Dolicanin Z, Djonov V, Lukic ML, Volarevic V. Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells. Liver Transpl. 2017;23(8):1040–1050.
14. Luz-Crawford P, Djoud F, Toupet K, Bony C, Franquesa M, Hoogduijn MJ, Jorgensen C, Noel D. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells. 2016;34(2):483–492.
15. Scuteria S, Salvi V, Lorenzi L, Piersigilli G, Lonardi S, Alotto D, Casarin S, Castagnoli C, Dander E, D’Amico G, Sozzani S, et al. Adaptive regulation of osteopontin production by dendritic cells through the bidirectional interaction with mesenchymal stromal cells. Front Immunol. 2018;9:1207.
16. Zhang L, Yu J, Wei W. Advance in targeted immunotherapy for graft-versus-host disease. Front Immunol. 2018;9:1087.
17. Munneke JM, Spruit MJ, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD. The potential of mesenchymal stromal cells as treatment for severe steroid-refractory acute graft-versus-host disease: a critical review of the literature. Transplantation. 2016;100(11):2309–2314.
18. von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N, Stolzel F, Parmentier S, Sockel K, Krech M, Schmitz M, et al. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome. Stem Cells. 2016;34(2):357–366.
19. Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, et al. Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. Br J Haematol. 2019;185(1):89–92.
20. Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, Wu X, Zhang Y, Fan Z, Zhou H, Liu C, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(1):97–104.
21. Li X, Gao Q, Feng Y, Zhang X. Developing role of B cells in the pathogenesis and treatment of chronic GVHD. Br J Haematol. 2019;184(3):323–336.
22. Zeiser R, Negrin RS. Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets. Blood. 2017;129(1):1–2.
23. Fan L, Hu C, Chen J, Cen P, Wang J, Li L. Interaction between mesenchymal stem cells and B-Cells. Int J Mol Sci. 2016;17(5):E650.
24. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499–3506.
25. Khare D, Or R, Resnick I, Barkatz C, Almog-Hazan O, Avni B. Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes. Front Immunol. 2018;9:3053.
26. Rosado MM, Bernardo ME, Scarsella M, Conforti A, Giorda E, Biagini S, Cascioli S, Rossi F, Guzzo I, Vivarelli M, Dello Strologo L, et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 2015;24(1):93–103.
27. Getahun A, Cambier JC. Non-antibody-secreting functions of B cells and their contribution to autoimmune disease. Annu Rev Cell Dev Biol. 2019.
28. Li H, Gu ZK, Li XS, Hou CM, Tang PH, Mao N. Functional and phenotypic alteration of intrasplenic lymphocytes affected by mesenchymal stem cells in a murine allosplenocyte transfusion model. Cell Transplant. 2007;16(1):85–95.
29. Guo Z, Li H, Li X, Yu X, Wang H, Tang P, Mao N. In vitro characteristics and in vivo immunosuppressive activity of compact bone-derived murine mesenchymal progenitor cells. Stem Cells. 2006;24(4):992–1000.
30. Palathumpat V, Dejbakhsh-Jones S, Holm B, Strober S. Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol. 1992;149(3):808–817.
31. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg M, et al. Mesenchymal stem cells for treatment of acute GVHD: what mice can teach us about man. Tissue Antigens. 2016;81(10):1390–1397.
32. Gonzalez-Amaro R, Cortes JR, Sanchez-Madrid F, Martin P. Is B lymphocytes as antigen-presenting cells. Arch Immunol Ther Exp (Warsz). 2008;56(2):77–83.
34. Funaro M, Messina M, Shabbir M, Wright P, Najjar S, Tabansky I, Stern JN. The role of B cells in multiple sclerosis: more than antibodies. Discov Med. 2016;22(122):251–255.
35. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. 2015;42(4):607–612.
36. Siracusa F, Durek P, McGrath MA, Sercan-Alp O, Rao A, Du W, Cendon C, Chang HD, Heinz GA, Mashreghi MF, Radbruch A, et al. CD69(+) memory T lymphocytes of the bone marrow and spleen express the signature transcripts of tissue-resident memory T lymphocytes. Eur J Immunol. 2019;49(6):966–968.
37. Murata K, Inami M, Hasegawa A, Kubo S, Kimura T, Yama-shita M, Hosokawa H, Nagao T, Suzuki K, Hashimoto K, Shinkai H, et al. CD69-null mice protected from arthritis induced with anti-type II collagen antibodies. Int Immunol. 2003;15(8):987–992.
38. Lugthart G, Melsen JE, Vervat C, van Ostaijen-Ten Dam MM, Corver WE, Roelen DL, van Bergen J, van Tol MJ, Lankester AC, Schilham MW. Human lymphoid tissues harbor a distinct CD69(+)CXCR6(+) NK Cell Population. J Immunol. 2016;197(1):78–84.
39. Lim KH, Chen CG, Chang YC, Chiang YH, Kao CW, Wang WT, Chang CY, Huang L, Lin CS, Cheng CC, Cheng HI, et al. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia. Oncotarget. 2017;8(20):32476–32491.
40. Alari-Pahissa E, Notario L, Lorente E, Vega-Ramos J, Justel A, Lopez D, Villadangos JA, Lauzurica P. CD69 does not affect the extent of T cell priming. PLoS One. 2012;7(10):e48593.
41. Ji YR, Yang ZX, Han ZB, Meng L, Liang L, Peng XM, Yang SG, Chi Y, Chen DD, Wang YW, Han ZC. Mesenchymal stem cells support proliferation and terminal differentiation of B cells. Cell Physiol Biochem. 2012;30(6):1526–1537.
42. Luk F, Carreras-Planella L, Korevaar SS, de Witte SFH, Borras FE, Betjes MGH, Baan CC, Hoogduijn MJ, Franquela M. Inflammatory conditions dictate the effect of mesenchymal stem or stromal cells on B cell function. Front Immunol. 2017;8:1042.
43. Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F, Mullen Y. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 2009;37(5):604–615.
44. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, Cometa A, Cioni M, Porretti L, Barberi W, Frassoni F, et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant. 2008;23(4):1196–1202.
45. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367–372.